Biomerica Stock Forecast, Price & News

Biomerica (NASDAQ:BMRA) Frequently Asked Questions

Is Biomerica a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biomerica in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Biomerica stock.
View analyst ratings for Biomerica or view top-rated stocks.

How has Biomerica's stock been impacted by Coronavirus?

Biomerica's stock was trading at $2.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BMRA stock has increased by 48.3% and is now trading at $4.30.
View which stocks have been most impacted by COVID-19.

Are investors shorting Biomerica?

Biomerica saw a decline in short interest in the month of October. As of October 29th, there was short interest totaling 1,070,000 shares, a decline of 18.9% from the October 14th total of 1,320,000 shares. Based on an average trading volume of 2,030,000 shares, the days-to-cover ratio is presently 0.5 days. Approximately 10.3% of the shares of the stock are sold short.
View Biomerica's Short Interest.

When is Biomerica's next earnings date?

Biomerica is scheduled to release its next quarterly earnings announcement on Thursday, January 13th 2022.
View our earnings forecast for Biomerica.

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) issued its quarterly earnings results on Friday, October, 15th. The company reported ($0.12) EPS for the quarter, hitting analysts' consensus estimates of ($0.12). The firm had revenue of $1.26 million for the quarter. Biomerica had a negative trailing twelve-month return on equity of 64.01% and a negative net margin of 86.94%.
View Biomerica's earnings history.

What price target have analysts set for BMRA?

2 analysts have issued 12-month target prices for Biomerica's shares. Their forecasts range from $10.00 to $13.00. On average, they expect Biomerica's share price to reach $11.50 in the next year. This suggests a possible upside of 167.4% from the stock's current price.
View analysts' price targets for Biomerica or view top-rated stocks among Wall Street analysts.

Who are Biomerica's key executives?

Biomerica's management team includes the following people:

• Zackary S. Irani, Chairman & Chief Executive Officer
• Steve Sloan, Chief Financial Officer & Treasurer
• Allen C. Barbieri, Executive Vice Chairman & Secretary

Who are some of Biomerica's key competitors?

Some companies that are related to Biomerica include Quotient (QTNT), OncoCyte (OCX), Aspira Women's Health (AWH), VolitionRx (VNRX), Nymox Pharmaceutical (NYMX), ImmuCell (ICCC), Achieve Life Sciences (ACHV), Trinity Biotech (TRIB), Navidea Biopharmaceuticals (NAVB), StageZero Life Sciences (GNWSD), ARCA biopharma (ABIO), StageZero Life Sciences (GNWSF), StageZero Life Sciences (SZLSF), Global WholeHealth Partners (GWHP) and Fuse Science (DROP).
View all of BMRA's competitors.

What other stocks do shareholders of Biomerica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Johnson & Johnson (JNJ), Ampio Pharmaceuticals (AMPE), OPKO Health (OPK), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Co-Diagnostics (CODX), FuelCell Energy (FCEL) and Trevena (TRVN).

What is Biomerica's stock symbol?

Biomerica trades on the NASDAQ under the ticker symbol "BMRA."

Who are Biomerica's major shareholders?

Biomerica's stock is owned by many different retail and institutional investors. Top institutional investors include Granahan Investment Management Inc. MA (8.24%), BlackRock Inc. (1.37%), GWM Advisors LLC (0.25%), Eudaimonia Partners LLC (0.09%), HCR Wealth Advisors (0.08%) and Belvedere Trading LLC (0.00%). Company insiders that own Biomerica stock include Catherine Coste and Mark A Sirgo.
View institutional ownership trends for Biomerica.

Which institutional investors are selling Biomerica stock?

BMRA stock was sold by a variety of institutional investors in the last quarter, including GWM Advisors LLC.
View insider buying and selling activity for Biomerica or view top insider-selling stocks.

Which institutional investors are buying Biomerica stock?

BMRA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Eudaimonia Partners LLC, HCR Wealth Advisors, Granahan Investment Management Inc. MA, and Belvedere Trading LLC.
View insider buying and selling activity for Biomerica or or view top insider-buying stocks.

How do I buy shares of Biomerica?

Shares of BMRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biomerica's stock price today?

One share of BMRA stock can currently be purchased for approximately $4.30.

How much money does Biomerica make?

Biomerica has a market capitalization of $53.80 million and generates $7.20 million in revenue each year. The company earns $-7.45 million in net income (profit) each year or ($0.52) on an earnings per share basis.

How many employees does Biomerica have?

Biomerica employs 45 workers across the globe.

What is Biomerica's official website?

The official website for Biomerica is www.biomerica.com.

Where are Biomerica's headquarters?

Biomerica is headquartered at 17571 Von Karman Avenue, Irvine CA, 92614.

How can I contact Biomerica?

Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The company can be reached via phone at (949) 645-2111 or via fax at 949-553-1231.